SEQ ID NO: 1 (amino acid sequence of PCT): | |
1 | APFRSALESS PADPATLSED EARLLLAALV QDYVQMKASE LEQEQEREGS |
51 | SLDSPRSKRC GNLSTCMLGT YTQDFNKFHT FPQTAIGVGA PGKKRDMSSD |
101 | LERDHRPHVS MPQNAN |
TABLE 1 | ||||||
Described anti-PCT antibodies and their use in immunoassays | ||||||
Immunogen | Epitope | |||||
(numbers refer | (numbers refer | tested in | tested | |||
to amino | to amino | sandwich | with | |||
acid positions | acid positions | immuno- | native | |||
Name | Source | in PCT 1-116) | in PCT 1-116) | assay | PCT | Reference |
anti- | Sheep | Calcitonin | GTYTQDFNKFH; | yes | yes | (Morgenthaler, |
Calcitonin | 69-79 | et al. Clin | ||||
Chem | ||||||
2002;48:788- | ||||||
90) | ||||||
anti- | mouse | Katacalcin | ERDHRPHVSM; | yes | yes | (Morgenthaler, |
katacalcin | 102-111 | et al. Clin | ||||
(QN05) | Chem | |||||
2002;48:788- | ||||||
90) | ||||||
PROC1 | rat | FRSALESSPADPATL | n.d. | yes | no | (Kramer, et al. |
3G3 | SEDE; 3-20 | Anal Bioanal | ||||
Chem | ||||||
2008;392:727- | ||||||
36) | ||||||
PROC4 | rat | SDLERDHRPHV; 99- | n.d. | yes | no | (Kramer, et al. |
6C6 etc | 109 | Anal Bioanal | ||||
Chem | ||||||
2008;392:727- | ||||||
36) | ||||||
R2B7 | rabbit | Amino-ProCT; | n.d. | no | yes | (Whang, et al. J |
antiserum | 1-57 | Clin | ||||
Endocrinol | ||||||
Metab | ||||||
1998;83:3296- | ||||||
301) | ||||||
295/3H12 | mouse | APFRLSALESC; | n.d. other than N- | yes | yes | DE 10 2007 |
etc. | 1-9 | terminal Alanin | 009 751 | |||
being required | ||||||
98-47/44 | mouse | DSPRSKRCGNLS; | n.d. | yes | yes | US 6451311 |
53-64 | ||||||
98-31/04 | mouse | VGAPGKKRDMSS; | n.d. | yes | yes | US 6451311 |
88-99 | ||||||
CT08 | mouse | Calcitonin | TYTQDFN; 70- | yes | yes | (Assicot, et al. |
76 | Lancet | |||||
1993;341:515- | ||||||
8; Ghillani et | ||||||
al, Cancer Res | ||||||
1989;49:6845- | ||||||
51) | ||||||
KC01 | mouse | Katacalcin | DMSSDLERDHR; | yes | yes | (Assicot, et al. |
96-106 | Lancet | |||||
1993;341:515- | ||||||
8; Ghillani, et | ||||||
al. Cancer Res | ||||||
1989;49:6845- | ||||||
51) |
TABLE 2 | ||||
Epitope mapping results: Observed binding signals | ||||
for the three antibodies to the shown peptides | ||||
representing subsequences of the entire PCT | ||||
sequence were related to the maximum binding | ||||
obtained per antibody (B/Bmax). | ||||
pep- | ||||
tide | ||||
# | sequence | FX1G5 | FW5H6 | FX7A7 |
1 | APFRSALESSPAD | 0.0% | 0.0% | 0.0% |
2 | FRSALESSPADPA | 0.0% | 0.0% | 0.0% |
3 | SALESSPADPATL | 0.0% | 0.0% | 0.0% |
4 | LESSPADPATLSE | 0.0% | 0.0% | 0.0% |
5 | SSPADPATLSEDE | 0.0% | 0.0% | 0.0% |
6 | PADPATLSEDEAR | 0.0% | 0.0% | 0.0% |
7 | DPATLSEDEARLL | 0.0% | 0.0% | 0.0% |
8 | ATLSEDEARLLLA | 0.0% | 0.1% | 0.0% |
9 | LSEDEARLLLAAL | 3.0% | 0.0% | 0.0% |
10 | EDEARLLLAALVQ | 0.3% | 0.0% | 0.0% |
11 | EARLLLAALVQDY | 1.7% | 0.0% | 0.0% |
12 | RLLLAALVQDYVQ | 25.0% | 57.3% | 0.2% |
13 | LLAALVQDYVQMK | 100.0% | 59.5% | 62.7% |
14 | AALVQDYVQMKAS | 11.9% | 14.7% | 0.0% |
15 | LVQDYVQMKASEL | 0.0% | 0.0% | 0.0% |
16 | QDYVQMKASELEQ | 0.0% | 0.0% | 0.0% |
17 | YVQMKASELEQEQ | 0.0% | 0.0% | 0.0% |
18 | QMKASELEQEQER | 0.0% | 0.0% | 0.0% |
19 | KASELEQEQEREG | 0.0% | 0.0% | 0.0% |
20 | SELEQEQEREGSS | 0.0% | 0.0% | 0.0% |
21 | LEQEQEREGSSLD | 0.0% | 0.1% | 0.0% |
22 | QEQEREGSSLDSP | 0.0% | 0.0% | 0.0% |
23 | QEREGSSLDSPRS | 0.0% | 0.0% | 0.0% |
24 | REGSSLDSPRSKR | 0.0% | 0.1% | 0.0% |
25 | GSSLDSPRSKRCG | 0.0% | 0.3% | 0.1% |
26 | SLDSPRSKRCGNL | 0.0% | 0.2% | 0.3% |
27 | DSPRSKRCGNLST | 0.0% | 0.0% | 0.2% |
28 | PRSKRCGNLSTCM | 0.0% | 0.0% | 0.2% |
29 | SKRCGNLSTCMLG | 0.0% | 0.0% | 0.0% |
30 | RCGNLSTCMLGTY | 0.0% | 0.0% | 0.2% |
31 | GNLSTCMLGTYTQ | 0.1% | 0.0% | 0.0% |
32 | LSTCMLGTYTQDF | 0.0% | 0.0% | 0.0% |
33 | TCMLGTYTQDFNK | 0.0% | 0.0% | 0.0% |
34 | MLGTYTQDFNKFH | 0.0% | 3.4% | 0.0% |
35 | GTYTQDFNKFHTF | 0.0% | 1.9% | 0.0% |
36 | YTQDFNKFHTFPQ | 0.0% | 0.1% | 0.0% |
37 | QDFNKFHTFPQTA | 0.4% | 0.0% | 0.0% |
38 | FNKFHTFPQTAIG | 0.0% | 0.1% | 0.0% |
39 | KFHTFPQTAIGVG | 0.2% | 0.0% | 0.0% |
40 | HTFPQTAIGVGAP | 0.0% | 0.0% | 0.0% |
41 | FPQTAIGVGAPGK | 0.1% | 0.0% | 0.0% |
42 | QTAIGVGAPGKKR | 1.0% | 0.1% | 0.1% |
43 | AIGVGAPGKKRDM | 0.0% | 0.0% | 0.0% |
44 | GVGAPGKKRDMSS | 0.0% | 0.0% | 0.0% |
45 | GAPGKKRDMSSDL | 0.0% | 0.6% | 0.0% |
46 | PGKKRDMSSDLER | 0.0% | 0.3% | 0.1% |
47 | KKRDMSSDLERDH | 0.0% | 0.0% | 0.0% |
48 | RDMSSDLERDHRP | 0.0% | 1.5% | 0.0% |
49 | MSSDLERDHRPHV | 1.8% | 1.5% | 1.9% |
50 | SDLERDHRPHVSM | 0.4% | 1.5% | 0.9% |
51 | LERDHRPHVSMPQ | 1.3% | 1.5% | 2.8% |
52 | RDHRPHVSMPQNA | 0.0% | 0.1% | 0.2% |
53 | DHRPHVSMPQNAN | 0.0% | 0.0% | 0.0% |
54 | APFRSALESSPADPATLSED | 0.2% | 0.0% | 0.0% |
55 | ALESSPADPATLSEDEARLL | 0.3% | 0.1% | 0.0% |
56 | PADPATLSEDEARLLLAALV | 0.0% | 0.0% | 0.0% |
57 | TLSEDEARLLLAALVQDYVQ | 64.4% | 64.7% | 49.9% |
58 | EARLLLAALVQDYVQMKASE | 74.6% | 100.0% | 100.0% |
59 | LAALVQDYVQMKASELEQEQ | 2.8% | 2.7% | 0.1% |
60 | QDYVQMKASELEQEQEREGS | 0.7% | 0.0% | 0.1% |
61 | MKASELEQEQEREGSSLDSP | 0.6% | 0.0% | 0.1% |
62 | LEQEQEREGSSLDSPRSKRC | 0.0% | 0.4% | 0.1% |
63 | EREGSSLDSPRSKRCGNLST | 0.0% | 0.2% | 0.0% |
64 | SLDSPRSKRCGNLSTCMLGT | 0.5% | 0.0% | 0.0% |
65 | RSKRCGNLSTCMLGTYTQDF | 0.9% | 0.2% | 0.0% |
66 | GNLSTCMLGTYTQDFNKFHT | 0.0% | 0.5% | 0.0% |
67 | CMLGTYTQDFNKFHTFPQTA | 0.0% | 0.1% | 0.0% |
68 | YTQDFNKFHTFPQTAIGVGA | 0.0% | 0.0% | 0.0% |
69 | NKFHTFPQTAIGVGAPGKKR | 4.8% | 0.3% | 0.9% |
70 | FPQTAIGVGAPGKKRDMSSD | 0.0% | 0.0% | 0.0% |
71 | IGVGAPGKKRDMSSDLERDH | 0.0% | 0.1% | 0.0% |
72 | PGKKRDMSSDLERDHRPHVS | 0.7% | 0.1% | 2.3% |
73 | DMSSDLERDHRPHVSMPQNA | 0.2% | 0.1% | 0.3% |
74 | MSSDLERDHRPHVSMPQNAN | 0.3% | 0.4% | 0.2% |